Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.
EP: 1.Overview of HER2-Targeting Agents in Breast Cancer and Treatment Selection Approaches
EP: 2.APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer
EP: 3.KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer
EP: 4.Exciting Developments in HER2+ Breast Cancer
EP: 5.Current Approaches to Treatment Sequencing in HER2+ Breast Cancer
EP: 6.Unmet Needs and Future Directions in HER2+ Breast Cancer
EP: 7.Risk Stratification and Treatment Selection in HER2+ Breast Cancer: The Current Treatment Landscape and NCCN Guideline Recommendations
EP: 8.Long-Term Pertuzumab Outcomes in HER2+ Breast Cancer: Insights from APHINITY 8-Year Data and NeoSphere Pooled Analysis
EP: 9.KATHERINE Trial: Long-Term Outcomes of T-DM1 vs Trastuzumab in HER2+ Breast Cancer with Residual Disease
EP: 10.The Expanding Treatment Armamentarium and Clinical Decision Making: ExteNET, DestinyBREAST-05, HER2CLIMB, and Other Emerging Trials
EP: 11.Unmet Needs and Future Directions in HER2+ Breast Cancer Management
Video content above is prompted by the following:
- Please provide some background on APHINITY 8-Year follow up data evaluating pertuzumab with adjuvant trastuzumab and chemotherapy in early HER2+ breast cancer.
- With a median follow up of 8.4 years, what are your impressions of the long-term safety and efficacy profile of pertuzumab?
- Is the IDFS benefit observed with pertuzumab sustained over the extended follow-up period?
- Does the addition of pertuzumab have a positive impact on quality of life for patients with HER2-positive early breast cancer, beyond just extending IDFS?
- Please review the rationale and study design for the NeoSphere pooled analysis study and discuss implications of these data on treatment landscape.
- Which treatment combinations were investigated and how did efficacy outcomes vary between the treatment arms? What are your impressions of these data?
- How did tumor size, node involvement, or biomarker positivity affect efficacy outcomes?
- What are your impressions of the safety data?
POSITIVE Trial Shows Breastfeeding is Possible During Endocrine Therapy Break in HR+ Breast Cancer
Published: September 18th 2024 | Updated: September 16th 2024Follow-up results from the POSITIVE trial showed that breastfeeding is achievable for patients with HR-positive breast cancer who conceived during a break from endocrine therapy.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
